Intuitive Surgical/$ISRG

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Intuitive Surgical

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.

Ticker

$ISRG
Sector
Primary listing

Employees

15,638

ISRG Metrics

BasicAdvanced
$163B
63.40
$7.17
1.65
-

What the Analysts think about ISRG

Analyst ratings (Buy, Hold, Sell) for Intuitive Surgical stock.

Bulls say / Bears say

In Q2 2025 Intuitive beat Wall Street estimates with revenue of $2.44 billion (+21% y/y) and adjusted EPS of $2.19 (+23% y/y), driven by a 17% rise in worldwide da Vinci procedures (Reuters)
Recurring instruments and accessories revenue grew 18.5% to $1.47 billion in Q2 2025, underpinned by 17% da Vinci, 52% Ion and 88% SP procedure growth, strengthening the high-margin consumables stream (Nasdaq)
In June and July 2025 Intuitive secured Japanese regulatory clearance and EU MDR certification for its next-gen da Vinci 5 system, broadening its addressable markets in two major global regions (SEC)
Tariff headwinds are set to erode Intuitive’s 2025 non-GAAP gross profit margin to 65%–66.5%, down from 69.1% in 2024, reflecting an estimated 1.7% drag on revenue and potentially impeding the company’s ability to win future hospital tenders (Reuters)
Placements of the Ion lung biopsy robot fell 30% year-over-year to 54 units in Q2 2025 versus 74 in Q2 2024, signaling a normalization in demand for the platform and slower adoption than earlier projections (Investors.com)
Management’s 2025 guidance calls for da Vinci procedure growth of 15.5%–17%, below the historical 17%–18% trend, indicating a potential deceleration in procedure volume momentum (Investors.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

ISRG Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ISRG Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ISRG

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs